← Leaderboards
Tian-Li Wang
Johns Hopkins University
$3,014,402
Attributed
$4,608,849
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $718K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,608,849 · 4
By mechanism
R01$3,796,803 · 2
P50$424,461 · 1
R21$387,585 · 1
Top collaborators
- Thomas Russell Pisanic Ii5 shared
- Ie-Ming Shih5 shared
- Tza-Huei Jeff Wang5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Cornelia L Trimble$7,319,162
- Ie-Ming Shih$14,895,140
- Vered Stearns$536,053
- Amanda Nickles Fader$1,935,907
- Charles W. Flexner$41,000,447
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryTumorWomanMalignant NeoplasmsTissuesNeoplastic CellTumor ProgressionCancer BiologyCollaborationsComplexSamplingBaseOperative Surgical ProceduresCancer TypeCarcinomaTrainingResearch PersonnelDiagnosisHigh RiskSerousTravelLaboratoriesMouse ModelMediating
Grant awards (14)
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$417,626
R01 · FY2025 · CA
Developmental Research Program$300,356
P50 · FY2025 · CA · contact PI
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$406,959
R01 · FY2024 · CA
Developmental Research Program$124,105
P50 · FY2024 · CA · contact PI
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$423,593
R01 · FY2023 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$433,937
R01 · FY2022 · CA
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women$443,815
R01 · FY2021 · CA
Characterizing Notch3 Signaling in Ovarian Cancer$340,300
R01 · FY2015 · CA · contact PI
TARGETING SPLEEN TYROSINE KINASE IN CHEMORESISTANT OVARIAN CARCINOMA$176,175
R21 · FY2015 · CA · contact PI
Characterizing Notch3 Signaling in Ovarian Cancer$330,091
R01 · FY2014 · CA · contact PI
TARGETING SPLEEN TYROSINE KINASE IN CHEMORESISTANT OVARIAN CARCINOMA$211,410
R21 · FY2014 · CA · contact PI
Characterizing Notch3 Signaling in Ovarian Cancer$319,882
R01 · FY2013 · CA · contact PI
Characterizing Notch3 Signaling in Ovarian Cancer$340,300
R01 · FY2012 · CA · contact PI
Characterizing Notch3 Signaling in Ovarian Cancer$340,300
R01 · FY2011 · CA · contact PI